ABDULLAH MUBARAK: Open Payments
NPI 1336109925 · TYLER, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$110,464 in 173 payments from 11 companies in 2025. Trend: 2023 $30,325 · 2024 $114,991 · 2025 $110,464
Speaker / faculty: $94,012Travel & lodging: $6,445Consulting: $5,470Food & beverage: $4,537
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 40 | $30,462 |
| Ipsen Biopharmaceuticals, Inc | 27 | $30,415 |
| Gilead Sciences, Inc. | 54 | $25,690 |
| ABBVIE INC. | 29 | $23,291 |
| Intercept Pharmaceuticals, Inc. | 12 | $253 |
| Kerecis Limited | 2 | $187 |
| Intra-Sana Laboratories | 3 | $60 |
| Novo Nordisk Inc | 2 | $37 |
| Mirum Pharmaceuticals, Inc. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
Products named: IQIRVO, REZDIFFRA, MAVYRET, Epclusa, Livdelzi, OCALIVA, Kerecis SurgiClose, RELTONE 200 MG.
Industry payments across TX — which companies pay providers there.
